Research programme: glycosylated antibodies - GlycoFi/Dartmouth

Drug Profile

Research programme: glycosylated antibodies - GlycoFi/Dartmouth

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator Dartmouth College; GlycoFi
  • Developer GlycoFi
  • Class
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Mar 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 25 Mar 2008 Discontinued - Preclinical for Cancer in Lebanon (unspecified route)
  • 23 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top